{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:33:13Z","timestamp":1787020393383,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["TMA2019CDF-2670"],"award-info":[{"award-number":["TMA2019CDF-2670"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Cytochrome P450 2D6 is involved in the metabolism of several important medicines including opioids. Variations in CYP2D6 have been implicated in drug response and according to the Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, dosing for CYP2D6 substrates should be based on variants carried by individuals. Although\n                      <jats:italic>CYP2D6<\/jats:italic>\n                      variations in Ghana had been previously recorded, not all variants have been reported in the Ghanaian population. In this exploratory study we set to investigate certain unreported variations in the Ghanaian population in addition to the previously reported ones and use that to understand the tramadol \u2018abuse\u2019 crisis that is currently being experienced in Ghana.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study employed a convenience sampling approach to include 106 unrelated participants who were recruited as part of the PHARMABIOME project. We successfully genotyped 106 samples using Iplex GOLD SNP genotyping protocol after extracting DNA from these individuals. Allele and diplotype frequencies were undertaken by counting from observed genotypes. Comparison of alleles reported from various studies were done.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Unreported alleles such as *3, *9 and *41 which are classified as no function and decreased function were observed in our study cohort. In addition, variants such as (*1, *2, *4, *5, *10, *17 and *29 were observed with different frequencies. Our study showed 26% representation of intermediate metabolizers (IM) and 2% poor metabolizers (PM) in the study population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The implications for informal sector workers who use tramadol for recreational purposes, is that IMs and PMs will overdose as they may have reduced analgesic effects which will translate into increased risks of unforeseen adverse events. We therefore propose that\n                      <jats:italic>CYP2D6<\/jats:italic>\n                      should be considered in opioid dosage while making use of these observed variations to implement new approaches to tackle the tramadol \u2018abuse crisis\u2019 in Ghana.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12920-023-01773-8","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T09:02:36Z","timestamp":1705914156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A consideration of CYP2D6 genetic variations in the Ghanaian population as a potential \u2018culprit\u2019 for the tramadol \u2018abuse crisis\u2019"],"prefix":"10.1186","volume":"17","author":[{"given":"Nicholas Ekow","family":"Thomford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna Aba","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel Badu","family":"Nyarko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Peter","family":"Biney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,22]]},"reference":[{"key":"1773_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00210-003-0832-2","volume":"369","author":"UM Zanger","year":"2004","unstructured":"Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol. 2004;369:23\u201337.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"5\u20136","key":"1773_CR2","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1159\/000326085","volume":"87","author":"W Leppert","year":"2011","unstructured":"Leppert W. CYP2D6 in the metabolism of opioids for mild to moderate pain. Pharmacology. 2011;87(5\u20136):274\u201385.","journal-title":"Pharmacology"},{"issue":"1","key":"1773_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/gim.2016.80","volume":"19","author":"A Gaedigk","year":"2017","unstructured":"Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Leeder JS. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med. 2017;19(1):69\u201376.","journal-title":"Genet Med"},{"issue":"6","key":"1773_CR4","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s40262-018-00731-3","volume":"58","author":"M Kinnunen","year":"2019","unstructured":"Kinnunen M, Piirainen P, Kokki H, Lammi P, Kokki M. Updated clinical pharmacokinetics and pharmacodynamics of Oxycodone. Clin Pharmacokinet. 2019;58(6):705\u201325.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1773_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/sj.tpj.6500406","volume":"7","author":"J Kirchheiner","year":"2007","unstructured":"Kirchheiner J, Schmidt H, Tzvetkov M, Keulen JT, L\u00f6tsch J, Roots I, Brockm\u00f6ller J. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 2007;7(4):257\u201365.","journal-title":"Pharmacogenomics J"},{"issue":"6","key":"1773_CR6","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/00008571-199912000-00005","volume":"9","author":"A Wennerholm","year":"1999","unstructured":"Wennerholm A, Johansson I, Massele AY, Lande M, Alm C, Aden-Abdi Y, Dahl ML, Ingelman-Sundberg M, Bertilsson L, Gustafsson LL. Decreased capacity for debrisoquine metabolism among black tanzanians: analyses of the CYP2D6 genotype and phenotype. Pharmacogenetics. 1999;9(6):707\u201314.","journal-title":"Pharmacogenetics"},{"issue":"4","key":"1773_CR7","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/clpt.2013.254","volume":"95","author":"KR Crews","year":"2014","unstructured":"Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, Haidar CE, Shen DD, Callaghan JT, Sadhasivam S, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014;95(4):376\u201382.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1773_CR8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.4314\/gmj.v50i2.1","volume":"50","author":"FK Boni","year":"2016","unstructured":"Boni FK, Afrane BA. Pain services and prescription of opioid Drugs in Ghana. Ghana Med J. 2016;50(2):62\u20132.","journal-title":"Ghana Med J"},{"issue":"1","key":"1773_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1741-7015-8-8","volume":"8","author":"D Lohman","year":"2010","unstructured":"Lohman D, Schleifer R, Amon JJ. Access to pain treatment as a human right. BMC Med. 2010;8(1):8.","journal-title":"BMC Med"},{"issue":"2 Suppl","key":"1773_CR10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.36076\/ppj.2008\/11\/S105","volume":"11","author":"R Benyamin","year":"2008","unstructured":"Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE, Vallejo R. Opioid Complications and side effects. Pain Physician. 2008;11(2 Suppl):105\u201320.","journal-title":"Pain Physician"},{"issue":"11","key":"1773_CR11","doi-asserted-by":"publisher","first-page":"e2042","DOI":"10.1002\/onco.13953","volume":"26","author":"N Reizine","year":"2021","unstructured":"Reizine N, Danahey K, Schierer E, Liu P, Middlestadt M, Ludwig J, Truong TM, van Wijk XMR, Yeo K-TJ, Malec M, et al. Impact of CYP2D6 pharmacogenomic status on Pain Control among opioid-treated oncology patients. Oncologist. 2021;26(11):e2042\u201352.","journal-title":"Oncologist"},{"key":"1773_CR12","doi-asserted-by":"crossref","unstructured":"Yiannakopoulou E. Pharmacogenomics and Opioid Analgesics: Clinical Implications. International Journal of Genomics 2015, 2015:368979.","DOI":"10.1155\/2015\/368979"},{"issue":"4","key":"1773_CR13","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/FTD.0b013e3182272b10","volume":"33","author":"S VanderVaart","year":"2011","unstructured":"VanderVaart S, Berger H, Sistonen J, Madadi P, Matok I, Gijsen VM, de Wildt SN, Taddio A, Ross CJ, Carleton BC, et al. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study. Ther Drug Monit. 2011;33(4):425\u201332.","journal-title":"Ther Drug Monit"},{"key":"1773_CR14","doi-asserted-by":"crossref","unstructured":"Cardia L, Calapai G, Quattrone D, Mondello C, Arcoraci V, Calapai F, Mannucci C, Mondello E. Preclinical and clinical pharmacology of Hydrocodone for Chronic Pain: a Mini Review. Front Pharmacol 2018, 9.","DOI":"10.3389\/fphar.2018.01122"},{"issue":"7","key":"1773_CR15","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/jat\/bku051","volume":"38","author":"NH Barakat","year":"2014","unstructured":"Barakat NH, Atayee RS, Best BM, Ma JD. Urinary hydrocodone and Metabolite distributions in Pain patients. J Anal Toxicol. 2014;38(7):404\u20139.","journal-title":"J Anal Toxicol"},{"issue":"7","key":"1773_CR16","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/FPC.0000000000000057","volume":"24","author":"L Gong","year":"2014","unstructured":"Gong L, Stamer UM, Tzvetkov MV, Altman RB, Klein TE. PharmGKB summary: tramadol pathway. Pharmacogenet Genomics. 2014;24(7):374\u201380.","journal-title":"Pharmacogenet Genomics"},{"issue":"13","key":"1773_CR17","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2165\/00003088-200443130-00004","volume":"43","author":"S Grond","year":"2004","unstructured":"Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879\u2013923.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1773_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1213\/ANE.0000000000001683","volume":"124","author":"K Miotto","year":"2017","unstructured":"Miotto K, Cho AK, Khalil MA, Blanco K, Sasaki JD, Rawson R. Trends in Tramadol: Pharmacology, Metabolism, and Misuse. Anesth Analgesia. 2017;124(1):44\u201351.","journal-title":"Anesth Analgesia"},{"issue":"10","key":"1773_CR19","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/s41431-021-00920-y","volume":"30","author":"M Matic","year":"2022","unstructured":"Matic M, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk AM, Houwink EJF, Mulder H, Rongen G, Weide JV, Wilffert B, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone). Eur J Hum Genet. 2022;30(10):1105\u201313.","journal-title":"Eur J Hum Genet"},{"issue":"12","key":"1773_CR20","doi-asserted-by":"publisher","first-page":"e0001045","DOI":"10.1371\/journal.pgph.0001045","volume":"2","author":"JAK Alhassan","year":"2022","unstructured":"Alhassan JAK. Where is the pain? A qualitative analysis of Ghana\u2019s opioid (tramadol) \u2018crisis\u2019 and youth perspectives. PLOS Global Public Health. 2022;2(12):e0001045.","journal-title":"PLOS Global Public Health"},{"issue":"4","key":"1773_CR21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/YCO.0000000000000712","volume":"34","author":"RM Krausz","year":"2021","unstructured":"Krausz RM, Westenberg JN, Ziafat K. The opioid Overdose crisis as a global health challenge. Curr Opin Psychiatry. 2021;34(4):405\u201312.","journal-title":"Curr Opin Psychiatry"},{"issue":"3","key":"1773_CR22","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/cpt.2749","volume":"113","author":"D Twesigomwe","year":"2023","unstructured":"Twesigomwe D, Dr\u00f6gem\u00f6ller BI, Wright GEB, Adebamowo C, Agongo G, Boua PR, Matshaba M, Paximadis M, Ramsay M, Simo G, et al. Characterization of CYP2D6 pharmacogenetic variation in sub-saharan African populations. Clin Pharmacol Ther. 2023;113(3):643\u201359.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1773_CR23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00228-021-03208-8","volume":"78","author":"J Miura","year":"2022","unstructured":"Miura J, Obua C, Abbo C, Tateishi T, Kaneko S. CYP2D6 genetic variation in Ugandans. Eur J Clin Pharmacol. 2022;78(1):155\u20137.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"1773_CR24","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/00008571-199912000-00006","volume":"9","author":"EU Griese","year":"1999","unstructured":"Griese EU, Asante-Poku S, Ofori-Adjei D, Mikus G, Eichelbaum M. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a west African population. Pharmacogenetics. 1999;9(6):715\u201323.","journal-title":"Pharmacogenetics"},{"key":"1773_CR25","doi-asserted-by":"crossref","unstructured":"Mehlotra RK, Gaedigk A, Howes RE, Rakotomanga TA, Ratsimbasoa AC, Zimmerman PA. CYP2D6 genetic variation and its implication for Vivax Malaria Treatment in Madagascar. Front Pharmacol 2021, 12.","DOI":"10.3389\/fphar.2021.654054"},{"issue":"9","key":"1773_CR26","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.3390\/cancers11091353","volume":"11","author":"JH Ahmed","year":"2019","unstructured":"Ahmed JH, Makonnen E, Fotoohi A, Aseffa A, Howe R, Aklillu E. CYP2D6 genotype predicts plasma concentrations of tamoxifen metabolites in Ethiopian Breast Cancer patients. Cancers. 2019;11(9):1353.","journal-title":"Cancers"},{"issue":"1","key":"1773_CR27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1471-2350-14-20","volume":"14","author":"TM Dodgen","year":"2013","unstructured":"Dodgen TM, Hochfeld WE, Fickl H, Asfaha SM, Durandt C, Rheeder P, Dr\u00f6gem\u00f6ller BI, Wright GEB, Warnich L, Labuschagne CDJ, et al. Introduction of the AmpliChip CYP450 test to a South African cohort: a platform comparative prospective cohort study. BMC Med Genet. 2013;14(1):20.","journal-title":"BMC Med Genet"},{"issue":"3","key":"1773_CR28","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1046\/j.1365-2125.1999.00019.x","volume":"48","author":"L Bathum","year":"1999","unstructured":"Bathum L, Skjelbo E, Mutabingwa TK, Madsen H, H\u00f8rder M, Br\u00f8sen K. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. Br J Clin Pharmacol. 1999;48(3):395\u2013401.","journal-title":"Br J Clin Pharmacol"},{"key":"1773_CR29","unstructured":"Dean L, Kane M. Tramadol Therapy and CYP2D6 Genotype. In: Medical Genetics Summaries Edited by Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ. Bethesda (MD): National Center for Biotechnology Information (US); 2012."},{"issue":"1","key":"1773_CR30","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41398-020-01129-1","volume":"11","author":"AB Koopmans","year":"2021","unstructured":"Koopmans AB, Braakman MH, Vinkers DJ, Hoek HW, van Harten PN. Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19. Translational Psychiatry. 2021;11(1):141.","journal-title":"Translational Psychiatry"},{"key":"1773_CR31","unstructured":"Kane M. CYP2D6 Overview: Allele and Phenotype Frequencies. Bethesda (MD): National Center for Biotechnology Information (US); 2012-; 2021."},{"issue":"1","key":"1773_CR32","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/bcp.13788","volume":"85","author":"T Haslemo","year":"2019","unstructured":"Haslemo T, Eliasson E, Juki\u0107 MM, Ingelman-Sundberg M, Molden E. Significantly lower CYP2D6 metabolism measured as the O\/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped scandinavian patients. Br J Clin Pharmacol. 2019;85(1):194\u2013201.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1773_CR33","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/cpt.1972","volume":"109","author":"T Frederiksen","year":"2021","unstructured":"Frederiksen T, Areberg J, Schmidt E, Bjerregaard Stage T, Br\u00f8sen K. Quantification of in vivo metabolic activity of CYP2D6 genotypes and alleles through Population Pharmacokinetic Analysis of Vortioxetine. Clin Pharmacol Ther. 2021;109(1):150\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1773_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1067\/mcp.2002.120239","volume":"71","author":"A Wennerholm","year":"2002","unstructured":"Wennerholm A, Dandara C, Sayi J, Svensson JO, Abdi YA, Ingelman-Sundberg M, Bertilsson L, Hasler J, Gustafsson LL. The african-specific CYP2D617 allele encodes an enzyme with changed substrate specificity. Clin Pharmacol Ther. 2002;71(1):77\u201388.","journal-title":"Clin Pharmacol Ther"},{"key":"1773_CR35","doi-asserted-by":"publisher","first-page":"3026983","DOI":"10.1155\/2021\/3026983","volume":"2021","author":"F Saapiire","year":"2021","unstructured":"Saapiire F, Namillah G, Tanye V, Abubakari A. The Insurgence of Tramadol Abuse among the most active Population in Jirapa Municipality: a study to assess the magnitude of the abuse and its contributory factors. Psychiatry J. 2021;2021:3026983.","journal-title":"Psychiatry J"},{"issue":"3","key":"1773_CR36","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40801-021-00247-6","volume":"8","author":"M Danso","year":"2021","unstructured":"Danso M, Anto F. Factors Associated with Tramadol abuse: a cross-sectional study among Commercial drivers and assistants in the Accra Metropolitan Area of Ghana. Drugs - Real World Outcomes. 2021;8(3):337\u201347.","journal-title":"Drugs - Real World Outcomes"},{"issue":"1","key":"1773_CR37","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13011-020-00292-4","volume":"15","author":"P Peprah","year":"2020","unstructured":"Peprah P, Agyemang-Duah W, Appiah-Brempong E, Akwasi AG, Morgan AK. With tramadol, I ride like a Jaguar: a qualitative study of motivations for non-medical purpose tramadol use among commercial vehicle operators in Kumasi, Ghana. Subst Abuse Treat Prev Policy. 2020;15(1):49.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"4","key":"1773_CR38","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1002\/nop2.353","volume":"6","author":"A-G Fuseini","year":"2019","unstructured":"Fuseini A-G, Afizu A, Yakubu YH, Nachinab G. Facilitators to the continuous abuse of tramadol among the youth: a qualitative study in Northern Ghana. Nurs Open. 2019;6(4):1388\u201398.","journal-title":"Nurs Open"},{"issue":"8","key":"1773_CR39","first-page":"1842","volume":"21","author":"DM Smith","year":"2019","unstructured":"Smith DM, Weitzel KW, Elsey AR, Langaee T, Gong Y, Wake DT, Duong BQ, Hagen M, Harle CA, Mercado E, et al. CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial. Genet Sci. 2019;21(8):1842\u201350.","journal-title":"Genet Sci"},{"issue":"5","key":"1773_CR40","doi-asserted-by":"publisher","first-page":"582","DOI":"10.3109\/10826084.2014.991406","volume":"50","author":"MA El-Hadidy","year":"2015","unstructured":"El-Hadidy MA, Helaly AM. Medical and Psychiatric effects of Long-Term dependence on high dose of tramadol. Subst Use Misuse. 2015;50(5):582\u20139.","journal-title":"Subst Use Misuse"},{"issue":"4","key":"1773_CR41","first-page":"411","volume":"26","author":"TB Mike","year":"2021","unstructured":"Mike TB, DeVault H, Blackford MG. Acute Tramadol Ingestion with transient acute kidney Injury in an adolescent female. J Pediatr Pharmacol Ther. 2021;26(4):411\u20133.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"7","key":"1773_CR42","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1080\/17425255.2020.1776700","volume":"16","author":"M Doostmohammadi","year":"2020","unstructured":"Doostmohammadi M, Rahimi H-R. ADME and toxicity considerations for tramadol: from basic research to clinical implications. Expert Opin Drug Metab Toxicol. 2020;16(7):627\u201340.","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-023-01773-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-023-01773-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-023-01773-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T09:07:48Z","timestamp":1705914468000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-023-01773-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1773"],"URL":"https:\/\/doi.org\/10.1186\/s12920-023-01773-8","relation":{},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,22]]},"assertion":[{"value":"15 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental protocols involving human data was in accordance with relevant national and international guidelines and regulations. This study received ethical approval from the Cape Coast Teaching Hospital Ethical Review Committee (CCTHERC\/EC\/2020\/2020\/109) under the PHARMABIOME project. All participants provided both written and verbal consent to be part of this study. All participants provided both written and oral informed consent before samples were taken.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"N\/A.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author information"}}],"article-number":"28"}}